Ray Moynihan

Summary

Publications

  1. ncbi request reprint Medicine, the media and monetary interests: the need for transparency and professionalism
    R Moynihan
    Australian Financial Review
    Med J Aust 173:631-4. 2000
  2. pmc Selling sickness: the pharmaceutical industry and disease mongering
    Ray Moynihan
    Australian Financial Review, GPO Box 506, Sydney, 2201, Australia
    BMJ 324:886-91. 2002
  3. pmc Alosetron: a case study in regulatory capture, or a victory for patients' rights?
    Ray Moynihan
    Australian Financial Review, GPO Box 506, Sydney 2201, NSW, Australia
    BMJ 325:592-5. 2002
  4. ncbi request reprint Pharmaceutical industry funding of educational events for pharmacists in Australia: an analysis of data from the first 6 months of a mandatory disclosure programme
    Jane Robertson
    Clinical Pharmacology, School of Medicine and Public Health, The University of Newcastle, Waratah, NSW, Australia
    Int J Pharm Pract 18:88-92. 2010
  5. pmc Drug maker urges group to lobby FDA on testosterone for women
    Ray Moynihan
    BMJ 329:1255. 2004
  6. pmc FDA advisers warn of more deaths if drug is relaunched
    Ray Moynihan
    BMJ 325:561. 2002
  7. pmc FDA's safety reform is greeted with scepticism
    Ray Moynihan
    BMJ 330:435. 2005
  8. pmc New free trade agreement sparks fight over drug pricing
    Ray Moynihan
    BMJ 330:213. 2005
  9. pmc The marketing of a disease: female sexual dysfunction
    Ray Moynihan
    BMJ 330:192-4. 2005
  10. pmc FDA panel rejects testosterone patch for women on safety grounds
    Ray Moynihan
    BMJ 329:1363. 2004

Detail Information

Publications41

  1. ncbi request reprint Medicine, the media and monetary interests: the need for transparency and professionalism
    R Moynihan
    Australian Financial Review
    Med J Aust 173:631-4. 2000
    ..If one of the media's roles is informing the community about the business of health and medicine in a fair and accurate way, a cultural change in medical journalism is required...
  2. pmc Selling sickness: the pharmaceutical industry and disease mongering
    Ray Moynihan
    Australian Financial Review, GPO Box 506, Sydney, 2201, Australia
    BMJ 324:886-91. 2002
  3. pmc Alosetron: a case study in regulatory capture, or a victory for patients' rights?
    Ray Moynihan
    Australian Financial Review, GPO Box 506, Sydney 2201, NSW, Australia
    BMJ 325:592-5. 2002
  4. ncbi request reprint Pharmaceutical industry funding of educational events for pharmacists in Australia: an analysis of data from the first 6 months of a mandatory disclosure programme
    Jane Robertson
    Clinical Pharmacology, School of Medicine and Public Health, The University of Newcastle, Waratah, NSW, Australia
    Int J Pharm Pract 18:88-92. 2010
    ..The aim of the study was to assess the extent of pharmacist participation in pharmaceutical industry-sponsored educational events in Australia...
  5. pmc Drug maker urges group to lobby FDA on testosterone for women
    Ray Moynihan
    BMJ 329:1255. 2004
  6. pmc FDA advisers warn of more deaths if drug is relaunched
    Ray Moynihan
    BMJ 325:561. 2002
  7. pmc FDA's safety reform is greeted with scepticism
    Ray Moynihan
    BMJ 330:435. 2005
  8. pmc New free trade agreement sparks fight over drug pricing
    Ray Moynihan
    BMJ 330:213. 2005
  9. pmc The marketing of a disease: female sexual dysfunction
    Ray Moynihan
    BMJ 330:192-4. 2005
  10. pmc FDA panel rejects testosterone patch for women on safety grounds
    Ray Moynihan
    BMJ 329:1363. 2004
  11. pmc The intangible magic of celebrity marketing
    Ray Moynihan
    PLoS Med 1:e42. 2004
  12. pmc The fight against disease mongering: generating knowledge for action
    Ray Moynihan
    University of Newcastle, Newcastle, New South Wales, Australia
    PLoS Med 3:e191. 2006
  13. pmc Obesity task force linked to WHO takes "millions" from drug firms
    Ray Moynihan
    BMJ 332:1412. 2006
  14. pmc Roche defends buying lavish meals for doctors at Sydney's restaurants
    Ray Moynihan
    BMJ 333:169. 2006
  15. pmc Attempt to undermine European ban on advertising drugs fails in France
    Ray Moynihan
    BMJ 334:279. 2007
  16. pmc Doctors' education: the invisible influence of drug company sponsorship
    Ray Moynihan
    University of Newcastle, New South Wales
    BMJ 336:416-7. 2008
  17. pmc Disease mongering is now part of the global health debate
    Ray Moynihan
    School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia
    PLoS Med 5:e106. 2008
  18. pmc Key opinion leaders: independent experts or drug representatives in disguise?
    Ray Moynihan
    University of Newcastle, Newcastle, New South Wales, Australia
    BMJ 336:1402-3. 2008
  19. pmc Drug maker's PR firm is force behind blood clot awareness campaign
    Ray Moynihan
    BMJ 336:1460-1. 2008
  20. doi request reprint Is the relationship between pharma and medical education on the rocks?
    Ray Moynihan
    University of Newcastle
    BMJ 337:a925. 2008
  21. pmc FDA panel approves one make of silicone breast implant in the US
    Ray Moynihan
    BMJ 330:919. 2005
  22. pmc Controversial disease dropped from Prozac product information
    Ray Moynihan
    BMJ 328:365. 2004
  23. pmc Drug company targets US state health officials
    Ray Moynihan
    BMJ 328:306. 2004
  24. pmc FDA advisory panel calls for suicide warnings over new antidepressants
    Ray Moynihan
    BMJ 328:303. 2004
  25. pmc Drug firms hype disease as sales ploy, industry chief claims
    Ray Moynihan
    BMJ 324:867. 2002
  26. pmc FDA fails to reduce accessibility of paracetamol despite 450 deaths a year
    Ray Moynihan
    BMJ 325:678. 2002
  27. pmc The making of a disease: female sexual dysfunction
    Ray Moynihan
    Australian Financial Review, GPO Box 506, Sydney 2201, NSW, Australia
    BMJ 326:45-7. 2003
  28. pmc Company launches campaign to "counter" BMJ claims
    Ray Moynihan
    BMJ 326:120. 2003
  29. pmc US seniors group attacks pharmaceutical industry "fronts"
    Ray Moynihan
    BMJ 326:351. 2003
  30. pmc Anti-Glaxo campaign heats up in United States
    Ray Moynihan
    BMJ 326:413. 2003
  31. pmc FDA officials argue over safety of new arthritis drug
    Ray Moynihan
    BMJ 326:565. 2003
  32. pmc Drug company sponsorship of education could be replaced at a fraction of its cost
    Ray Moynihan
    BMJ 326:1163. 2003
  33. pmc Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: entanglement
    Ray Moynihan
    BMJ 326:1189-92. 2003
  34. pmc Who pays for the pizza? Redefining the relationships between doctors and drug companies. 2: Disentanglement
    Ray Moynihan
    BMJ 326:1193-6. 2003
  35. ncbi request reprint Making medical journalism healthier
    Ray Moynihan
    Lancet 361:2097-8. 2003
  36. pmc Global consulting firm calls for revolution in drug marketing
    Ray Moynihan
    BMJ 327:468. 2003
  37. pmc Cochrane at crossroads over drug company sponsorship
    Ray Moynihan
    BMJ 327:924-6. 2003
  38. pmc Safety concerns about breast implants persist
    Ray Moynihan
    BMJ 327:947. 2003
  39. pmc Cochrane plans to allay fears over industry influence
    Ray Moynihan
    BMJ 327:1005. 2003
  40. pmc Should drug companies be allowed to sponsor Cochrane reviews?
    Ray Moynihan
    CMAJ 169:1201. 2003
  41. pmc Too much medicine?
    Ray Moynihan
    BMJ 324:859-60. 2002